Background: Retinoic acid, the intracellular metabolite of vitamin A, induces differentiation in glioblastoma cultures and recognizes nuclear retinoic acid (RA) receptors in human glial cells. Its degradation can be inhibited by the oral steroid synthesis modulator liarozole or R75251 (5-[(3-chlorophenyl) (lH-imidazole-l-yl)methyl]-lH-benzimidazole HC1). Measured by 3H-thymidine incorporation, liarozole also exhibits an intrinsic attenuating effect on glioblastoma growth in vitro. Patients and Method: Ten patients with primary malignant brain tumors have entered an open oral therapeutic pilot study with 13-cis-retinoic acid (isotre-tinoinINN; Roaccutan® Roche) and the catabolic inhibitor liarozole. Results: Side effects such as cheilitis, conjunctivitis, and desquamation dose-depend-ently correlated with plasma levels and could be regularly used for dose adjustments. The combined therapy produced and maintained elevated plasma concentrations and clinical retinoid effects with fractions of formerly necessary 13-cis-RA doses. In vivo, 75-150 mg liarozole combined with 5-20 mg 13-cis-RA daily increased plasma 13-cis-RA and 4-oxo-13-cis-RA levels more than threefold. Long-term all-trans-RA therapy without liarozole leads to a progressive downregulation of plasma RA levels. Such a decrease may be prevented by combining all-trans-RA with its catabolic inhibitor liarozole (Janssen). Conclusion: First clinical experience recommends liarozole for either 13-cis-or all-trans RA therapy in retinoid-sensitive malignancies such as neuro-ectodermal glioma or acute promyelocytic leukemia.